A Phase IIb, Single Arm, Multicenter Trial of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
The goal of this study is to learn more about the effectiveness of the study drug, sacituzumab govitecan-hziy, in Chinese participants with metastatic triple-negative breast cancer (mTNBC) who received at least 2 systemic chemotherapy regimens.
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
Metastatic Triple-negative Breast Cancer
Gender
N/A
Date
October 2020 - August 2021
Study Type
Interventional
Study Phase
Phase 2
Product
Sacituzumab Govitecan-hziy
Beijing, Beijing, China, 100021
Shenyang, Liaoning, China
Hangzhou, Zhejiang, China
Beijing, China, 100853
Changchun, China, 130021
Changsha, China, 410013
Chengdu, China
Chongqing, China, 404100
Guangzhou, China, 510000
Guangzhou, China, 510120
Hangzhou, China, 310022
Hefei, China, 230001
Hefei, China, 230022
Shenyang, China, 110001
Tianjin, China, 300060
Wuhan, China, 430000
Xi'an, China, 710061
Share Trial